Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study

Hankil Lee, Seon Young Park, Andrew Clark, Frédéric Debellut, C. Pecenka, Dong Soo Kim, Hwang Min Kim, Ji Hong Kim, Hyeonseok Cho, Ah Young Kim, Minjun Lee, Sun Young Jung, Baik Lin Seong, Hye Young Kang

Research output: Contribution to journalArticle

Abstract

Rotavirus is a leading cause of severe gastroenteritis among children younger than 5 years in South Korea. Two rotavirus vaccines (RVs), pentavalent human-bovine reassortant vaccine (Rotateq®; RV5) and attenuated human strain originated monovalent vaccine (Rotarix®; RV1), have been available for voluntary vaccination using out-of-pocket payment since 2007 and 2008, respectively. Yet, RVs are not included in the National Immunization Program (NIP), partly because of the low associated mortality rate. We assessed the cost-effectiveness of RVs to assist the evidence-based decision-making process for NIP implementation in South Korea. Using a transparent age-structured static cohort model, we simulated the experience of ten annual birth cohorts of South Korean children from 2018 to 2027. Model inputs included rotavirus gastroenteritis (RVGE) incidence and mortality rates, RVGE treatment costs, vaccine coverage and timeliness, and vaccine effectiveness and price. The incremental costs of including RVs in the NIP compared to no vaccination were 59,662,738 USD and 152,444,379 USD for RV1 and RV5, respectively. The introduction of RV1 and RV5 can prevent 4799 disability-adjusted life years (DALYs) and 5068 DALYs. From the societal perspective, the incremental cost-effectiveness ratios (ICERs) for adopting RV into the NIP versus no vaccination were 12,432 USD per DALY averted for RV1 and 30,081 USD per DALY averted for RV 5. The weighted average for the ICERs of the two vaccines computed using the market share of each vaccine in the current voluntary use as a weight, was 21,698 USD per DALY averted. The estimated ICER was below 1 × gross domestic product per capita (30,000 USD), which has been a commonly used willingness-to-pay threshold for health care technology assessment in South Korea, suggesting that introducing RVs into the NIP would be cost-effective.

Original languageEnglish
Pages (from-to)4987-4995
Number of pages9
JournalVaccine
Volume37
Issue number35
DOIs
Publication statusPublished - 2019 Aug 14

Fingerprint

Rotavirus Vaccines
Immunization Programs
Rotavirus
gastroenteritis
Gastroenteritis
cost effectiveness
Cost-Benefit Analysis
Quality-Adjusted Life Years
immunization
Vaccination
vaccination
vaccines
Mortality
disability-adjusted life year
Vaccines
Republic of Korea
South Korea
Gross Domestic Product
Costs and Cost Analysis
Biomedical Technology Assessment

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Lee, Hankil ; Park, Seon Young ; Clark, Andrew ; Debellut, Frédéric ; Pecenka, C. ; Kim, Dong Soo ; Kim, Hwang Min ; Kim, Ji Hong ; Cho, Hyeonseok ; Kim, Ah Young ; Lee, Minjun ; Jung, Sun Young ; Seong, Baik Lin ; Kang, Hye Young. / Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality : A South Korean study. In: Vaccine. 2019 ; Vol. 37, No. 35. pp. 4987-4995.
@article{337d646067314a48bce667cd06e5880d,
title = "Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study",
abstract = "Rotavirus is a leading cause of severe gastroenteritis among children younger than 5 years in South Korea. Two rotavirus vaccines (RVs), pentavalent human-bovine reassortant vaccine (Rotateq{\circledR}; RV5) and attenuated human strain originated monovalent vaccine (Rotarix{\circledR}; RV1), have been available for voluntary vaccination using out-of-pocket payment since 2007 and 2008, respectively. Yet, RVs are not included in the National Immunization Program (NIP), partly because of the low associated mortality rate. We assessed the cost-effectiveness of RVs to assist the evidence-based decision-making process for NIP implementation in South Korea. Using a transparent age-structured static cohort model, we simulated the experience of ten annual birth cohorts of South Korean children from 2018 to 2027. Model inputs included rotavirus gastroenteritis (RVGE) incidence and mortality rates, RVGE treatment costs, vaccine coverage and timeliness, and vaccine effectiveness and price. The incremental costs of including RVs in the NIP compared to no vaccination were 59,662,738 USD and 152,444,379 USD for RV1 and RV5, respectively. The introduction of RV1 and RV5 can prevent 4799 disability-adjusted life years (DALYs) and 5068 DALYs. From the societal perspective, the incremental cost-effectiveness ratios (ICERs) for adopting RV into the NIP versus no vaccination were 12,432 USD per DALY averted for RV1 and 30,081 USD per DALY averted for RV 5. The weighted average for the ICERs of the two vaccines computed using the market share of each vaccine in the current voluntary use as a weight, was 21,698 USD per DALY averted. The estimated ICER was below 1 × gross domestic product per capita (30,000 USD), which has been a commonly used willingness-to-pay threshold for health care technology assessment in South Korea, suggesting that introducing RVs into the NIP would be cost-effective.",
author = "Hankil Lee and Park, {Seon Young} and Andrew Clark and Fr{\'e}d{\'e}ric Debellut and C. Pecenka and Kim, {Dong Soo} and Kim, {Hwang Min} and Kim, {Ji Hong} and Hyeonseok Cho and Kim, {Ah Young} and Minjun Lee and Jung, {Sun Young} and Seong, {Baik Lin} and Kang, {Hye Young}",
year = "2019",
month = "8",
day = "14",
doi = "10.1016/j.vaccine.2019.07.030",
language = "English",
volume = "37",
pages = "4987--4995",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "35",

}

Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality : A South Korean study. / Lee, Hankil; Park, Seon Young; Clark, Andrew; Debellut, Frédéric; Pecenka, C.; Kim, Dong Soo; Kim, Hwang Min; Kim, Ji Hong; Cho, Hyeonseok; Kim, Ah Young; Lee, Minjun; Jung, Sun Young; Seong, Baik Lin; Kang, Hye Young.

In: Vaccine, Vol. 37, No. 35, 14.08.2019, p. 4987-4995.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality

T2 - A South Korean study

AU - Lee, Hankil

AU - Park, Seon Young

AU - Clark, Andrew

AU - Debellut, Frédéric

AU - Pecenka, C.

AU - Kim, Dong Soo

AU - Kim, Hwang Min

AU - Kim, Ji Hong

AU - Cho, Hyeonseok

AU - Kim, Ah Young

AU - Lee, Minjun

AU - Jung, Sun Young

AU - Seong, Baik Lin

AU - Kang, Hye Young

PY - 2019/8/14

Y1 - 2019/8/14

N2 - Rotavirus is a leading cause of severe gastroenteritis among children younger than 5 years in South Korea. Two rotavirus vaccines (RVs), pentavalent human-bovine reassortant vaccine (Rotateq®; RV5) and attenuated human strain originated monovalent vaccine (Rotarix®; RV1), have been available for voluntary vaccination using out-of-pocket payment since 2007 and 2008, respectively. Yet, RVs are not included in the National Immunization Program (NIP), partly because of the low associated mortality rate. We assessed the cost-effectiveness of RVs to assist the evidence-based decision-making process for NIP implementation in South Korea. Using a transparent age-structured static cohort model, we simulated the experience of ten annual birth cohorts of South Korean children from 2018 to 2027. Model inputs included rotavirus gastroenteritis (RVGE) incidence and mortality rates, RVGE treatment costs, vaccine coverage and timeliness, and vaccine effectiveness and price. The incremental costs of including RVs in the NIP compared to no vaccination were 59,662,738 USD and 152,444,379 USD for RV1 and RV5, respectively. The introduction of RV1 and RV5 can prevent 4799 disability-adjusted life years (DALYs) and 5068 DALYs. From the societal perspective, the incremental cost-effectiveness ratios (ICERs) for adopting RV into the NIP versus no vaccination were 12,432 USD per DALY averted for RV1 and 30,081 USD per DALY averted for RV 5. The weighted average for the ICERs of the two vaccines computed using the market share of each vaccine in the current voluntary use as a weight, was 21,698 USD per DALY averted. The estimated ICER was below 1 × gross domestic product per capita (30,000 USD), which has been a commonly used willingness-to-pay threshold for health care technology assessment in South Korea, suggesting that introducing RVs into the NIP would be cost-effective.

AB - Rotavirus is a leading cause of severe gastroenteritis among children younger than 5 years in South Korea. Two rotavirus vaccines (RVs), pentavalent human-bovine reassortant vaccine (Rotateq®; RV5) and attenuated human strain originated monovalent vaccine (Rotarix®; RV1), have been available for voluntary vaccination using out-of-pocket payment since 2007 and 2008, respectively. Yet, RVs are not included in the National Immunization Program (NIP), partly because of the low associated mortality rate. We assessed the cost-effectiveness of RVs to assist the evidence-based decision-making process for NIP implementation in South Korea. Using a transparent age-structured static cohort model, we simulated the experience of ten annual birth cohorts of South Korean children from 2018 to 2027. Model inputs included rotavirus gastroenteritis (RVGE) incidence and mortality rates, RVGE treatment costs, vaccine coverage and timeliness, and vaccine effectiveness and price. The incremental costs of including RVs in the NIP compared to no vaccination were 59,662,738 USD and 152,444,379 USD for RV1 and RV5, respectively. The introduction of RV1 and RV5 can prevent 4799 disability-adjusted life years (DALYs) and 5068 DALYs. From the societal perspective, the incremental cost-effectiveness ratios (ICERs) for adopting RV into the NIP versus no vaccination were 12,432 USD per DALY averted for RV1 and 30,081 USD per DALY averted for RV 5. The weighted average for the ICERs of the two vaccines computed using the market share of each vaccine in the current voluntary use as a weight, was 21,698 USD per DALY averted. The estimated ICER was below 1 × gross domestic product per capita (30,000 USD), which has been a commonly used willingness-to-pay threshold for health care technology assessment in South Korea, suggesting that introducing RVs into the NIP would be cost-effective.

UR - http://www.scopus.com/inward/record.url?scp=85069005956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069005956&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.07.030

DO - 10.1016/j.vaccine.2019.07.030

M3 - Article

C2 - 31326252

AN - SCOPUS:85069005956

VL - 37

SP - 4987

EP - 4995

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 35

ER -